KR102673031B1 - 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물 - Google Patents

피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR102673031B1
KR102673031B1 KR1020210123331A KR20210123331A KR102673031B1 KR 102673031 B1 KR102673031 B1 KR 102673031B1 KR 1020210123331 A KR1020210123331 A KR 1020210123331A KR 20210123331 A KR20210123331 A KR 20210123331A KR 102673031 B1 KR102673031 B1 KR 102673031B1
Authority
KR
South Korea
Prior art keywords
methyl
benzamide
compound
pyridin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020210123331A
Other languages
English (en)
Korean (ko)
Other versions
KR20220036895A (ko
Inventor
박영준
박성준
유혜빈
송현남
윤시은
박소진
김준우
윤성일
Original Assignee
주식회사 엑세쏘바이오파마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엑세쏘바이오파마 filed Critical 주식회사 엑세쏘바이오파마
Publication of KR20220036895A publication Critical patent/KR20220036895A/ko
Application granted granted Critical
Publication of KR102673031B1 publication Critical patent/KR102673031B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020210123331A 2020-09-16 2021-09-15 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물 Active KR102673031B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200119100 2020-09-16
KR20200119100 2020-09-16

Publications (2)

Publication Number Publication Date
KR20220036895A KR20220036895A (ko) 2022-03-23
KR102673031B1 true KR102673031B1 (ko) 2024-06-07

Family

ID=80777269

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210123331A Active KR102673031B1 (ko) 2020-09-16 2021-09-15 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물

Country Status (11)

Country Link
US (1) US12590098B2 (https=)
EP (1) EP4215533B1 (https=)
JP (1) JP7824667B2 (https=)
KR (1) KR102673031B1 (https=)
CN (1) CN116137815B (https=)
AU (1) AU2021344164A1 (https=)
BR (1) BR112023004179A2 (https=)
CA (1) CA3190461A1 (https=)
IL (1) IL300920A (https=)
MX (1) MX2023003087A (https=)
WO (1) WO2022060094A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
US20070135461A1 (en) 2005-12-13 2007-06-14 Rodgers James D Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR100853975B1 (ko) 2004-08-31 2008-08-25 에프. 호프만-라 로슈 아게 3-페닐 디히드로피리미도[4,5-ｄ]피리미디논의 아미드유도체, 이의 제조 방법 및 약제로서의 용도
WO2018009544A1 (en) 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29439A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
RU2007147917A (ru) * 2005-06-10 2009-07-20 Айрм Ллк (Bm) Соединения, поддерживающие плюрипотентность эмбриональных стволовых клеток
GB201315072D0 (en) 2013-08-23 2013-10-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders
KR102591947B1 (ko) * 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
KR102382613B1 (ko) * 2020-01-15 2022-04-06 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
KR100853975B1 (ko) 2004-08-31 2008-08-25 에프. 호프만-라 로슈 아게 3-페닐 디히드로피리미도[4,5-ｄ]피리미디논의 아미드유도체, 이의 제조 방법 및 약제로서의 용도
US20070135461A1 (en) 2005-12-13 2007-06-14 Rodgers James D Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2018009544A1 (en) 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem, 2018, 61, 8353-8373.*

Also Published As

Publication number Publication date
EP4215533B1 (en) 2026-02-11
CN116137815A (zh) 2023-05-19
BR112023004179A2 (pt) 2023-04-11
US20230348474A1 (en) 2023-11-02
JP7824667B2 (ja) 2026-03-05
KR20220036895A (ko) 2022-03-23
EP4215533A4 (en) 2024-12-18
IL300920A (en) 2023-04-01
WO2022060094A1 (ko) 2022-03-24
JP2023541052A (ja) 2023-09-27
CN116137815B (zh) 2025-08-19
CA3190461A1 (en) 2022-03-24
MX2023003087A (es) 2023-04-14
AU2021344164A9 (en) 2024-03-21
AU2021344164A1 (en) 2023-05-04
US12590098B2 (en) 2026-03-31
EP4215533A1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
US9006257B2 (en) Bicyclic compounds as mPGES-1 inhibitors
US9024021B2 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
TWI385165B (zh) 經二取代之呔猬狀途徑拮抗劑
US8940756B2 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US11932647B2 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
US20090099190A1 (en) Kinase inhibitors useful for the treatment of proliferative diseases
US20120329796A1 (en) Compounds useful for treating premature aging and in particular progeria
JP2021506735A (ja) 新規ｍａｐ４ｋ１阻害剤
US12479850B2 (en) Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof
US12312337B2 (en) Compounds and methods for treating cancer
US20240228491A1 (en) Methionine adenosyltransferase inhibitor, preparation method therefor and application thereof
US20210040114A1 (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
KR102673031B1 (ko) 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물
US20180036317A1 (en) Method of treating conditions with kinase inhibitors
TW202432118A (zh) 蛋白質酪胺酸磷酸酶抑制劑、其組合物及使用方法
TW202246259A (zh) 吡唑醯胺衍生物
WO2022171139A1 (zh) 一种巨环化合物、药物组合物以及其用途
WO2020004518A1 (ja) 新規ｐｄｅ４阻害剤
US20250221979A1 (en) Novel heterocyclic compound
HK40095524A (zh) 吡唑酰胺衍生物
US20260070911A1 (en) Inhibitors of tam receptors
TW202231639A (zh) Ｂｒｕｔｏｎ＇ｓ酪氨酸激酶抑制劑及其應用
US20220389010A1 (en) Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20210915

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231004

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240516

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240603

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240603

End annual number: 3

Start annual number: 1

PG1601 Publication of registration